Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.
Whitehawk Therapeutics has raised $87.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Whitehawk Therapeutics's investors include Vivo Capital, OrbiMed, RTW Investments, Decheng Capital, Ally Bridge Group.
Whitehawk Therapeutics is headquartered in Pacific Palisades, United States.
Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.
Whitehawk Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Whitehawk Therapeutics — Funding & Investors." VCBacked, May 13, 2026, https://www.vcbacked.co/company/whitehawk-therapeutics. Accessed July 20, 2026.
VCBacked. (2026). Whitehawk Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/whitehawk-therapeutics
{{cite web |title=Whitehawk Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/whitehawk-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated